FYERS
Home
/
Stocks
/
Profit Loss
/
Mankind Pharma Profit & Loss

Mankind Pharma Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
₹4031 Cr₹3443 Cr₹3567 Cr₹3697 Cr₹3570 Cr₹3079 Cr₹3199 Cr₹3061 Cr₹2868 Cr₹2422 Cr₹2607 Cr₹2708 Cr₹2579 Cr₹2053 Cr₹2091 Cr₹2426 Cr₹2180 Cr₹1726 Cr
₹45 Cr₹114 Cr₹73 Cr₹92 Cr₹80 Cr₹251 Cr₹77 Cr₹109 Cr₹99 Cr₹92 Cr₹70 Cr₹60 Cr₹59 Cr₹48 Cr₹37 Cr₹27 Cr₹17 Cr₹34 Cr
₹4076 Cr₹3557 Cr₹3640 Cr₹3789 Cr₹3650 Cr₹3331 Cr₹3276 Cr₹3170 Cr₹2967 Cr₹2514 Cr₹2677 Cr₹2768 Cr₹2637 Cr₹2100 Cr₹2128 Cr₹2453 Cr₹2197 Cr₹1759 Cr
₹3200 Cr₹2736 Cr₹2870 Cr₹2998 Cr₹2942 Cr₹2627 Cr₹2570 Cr₹2315 Cr₹2299 Cr₹1936 Cr₹2110 Cr₹2122 Cr₹2011 Cr₹1721 Cr₹1739 Cr₹1914 Cr₹1802 Cr₹1488 Cr
₹1101 Cr₹1044 Cr₹992 Cr₹1013 Cr₹927 Cr₹935 Cr₹893 Cr₹956 Cr₹771 Cr₹678 Cr₹677 Cr₹743 Cr₹713 Cr₹464 Cr₹474 Cr₹618 Cr₹473 Cr₹318 Cr
₹110 Cr₹142 Cr₹157 Cr₹170 Cr₹171 Cr₹191 Cr₹221 Cr₹7 Cr₹11 Cr₹9 Cr₹9 Cr₹9 Cr₹6 Cr₹5 Cr₹13 Cr₹10 Cr₹16 Cr₹13 Cr
₹766 Cr₹656 Cr₹506 Cr₹622 Cr₹537 Cr₹513 Cr₹485 Cr₹849 Cr₹657 Cr₹570 Cr₹558 Cr₹638 Cr₹620 Cr₹375 Cr₹377 Cr₹529 Cr₹378 Cr₹258 Cr
₹570 Cr₹556 Cr₹411 Cr₹518 Cr₹441 Cr₹422 Cr₹381 Cr₹656 Cr₹539 Cr₹474 Cr₹455 Cr₹508 Cr₹489 Cr₹291 Cr₹293 Cr₹419 Cr₹294 Cr₹188 Cr

Share Price Live Stats

Open (₹)2,366.50
Volume (₹)87,887.00
High (₹)2,390.00
Upper Circuit2,605.60
Low (₹)2,327.30
Lower Circuit2,132.00
Prev Close2,368.80
52W High (₹)2,674.00
Price2,331.00
52W Low (₹)1,909.70

Share Market Cap & Key Ratios Overview

M.Cap (₹)96859.10 Cr
Div. Yield (%)0.04
PE Ratio47.42
Debt to Equity0.37
Price to Book5.09
Book Value393.72
EPS (TTM)49.45
Face Value1.00
ROE (%)12.69

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1902.3-17.7 (-0.92%)
1896.80
1984.80
4,56,833Cr
9148-91 (-0.98%)
9087
9467
2,45,426Cr
4832-218 (-4.32%)
4823
5066
1,87,320Cr
1126.7-64.3 (-5.40%)
1125.10
1187
1,13,217Cr
1380.6-42.9 (-3.01%)
1376
1426.10
1,12,212Cr
1844-94.5 (-4.87%)
1811.70
1949
1,01,155Cr
2108.1-63.4 (-2.92%)
2107
2192
97,626Cr
2331-51.9 (-2.18%)
2327.30
2419.20
96,859Cr
1156.9-21.1 (-1.79%)
1154.40
1179.90
96,406Cr
1657.9+12.6 (0.77%)
1622.60
1717
93,614Cr

Key Highlights of Mankind Pharma Ltd’s P&L

In 2026-03-31, Mankind Pharma Ltd reported total revenue of ₹14636.39Cr, compared with ₹12744.19Cr in 2025-03-31, reflecting Mankind Pharma Ltd turnover.

Depreciation was ₹886.18Cr and finance costs were ₹644.25Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹2332.68Cr in 2026-03-31 as compared to ₹2516.33Cr in 2025-03-31.

Net Profit (PAT) was ₹1912.93Cr in 2026-03-31 compared with ₹1990.96Cr in 2025-03-31.

Earnings per share (EPS) were ₹46.34 in 2026-03-31, compared with ₹48.25 in 2025-03-31.